1-6 of 6
Sevgi Kalayoglu Besisik
Close
Sort by
Journal Articles

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 Ithaca Study

Maria-Victoria Mateos, Paula Rodriguez Otero, Youngil Koh, Joaquin Martinez-Lopez, Gurdeep Parmar, H. Miles Prince, Hang Quach, Paz Ribas, Emil Hermansen, Vania T.M. Hungria, Sevgi Kalayoglu Besisik, Jin Seok Kim, Xavier Leleu, Valdas Pečeliūnas, Fredrik Schjesvold, Omur G. Sevindik, Tatiana Lavrova, Franck Dubin, Christine Devisme, Lucie Lepine, Sandrine Macé, Mony Morisse, Irene Ghobrial
Journal: Blood
Blood (2022) 140 (Supplement 1): 7317–7319.
https://doi.org/10.1182/blood-2022-157302
Published: 2022
Journal Articles

An Interim Analysis of the Turkish Myeloma Registry Among the Patients Who Have Received up to Two Lines of Therapy

Omur Gokmen Sevindik, Zubeyde Nur Ozkurt, Can Boga, Sevgi Kalayoglu Besisik, Yildiz Ipek, Ayfer Geduk, Aybuke Harmandali, Ayse Salihoglu, Handan haydaroglu Sahin, Mehmet Sönmez, Filiz Vural, Olga Meltem Akay, Meltem Kurt Yuksel, Senem Maral, Omer Ekinci, Onur Hakki Kirkizlar, Atakan Tekinalp, Nazli Demir, Mustafa Merter, Guray Saydam, İnci Alacacıoğlu, Zeynep Arzu Yegin, Mutlu Kasar, Metban Mastanzade, Guner Hayri Ozsan
Journal: Blood
Blood (2021) 138 (Supplement 1): 4730.
https://doi.org/10.1182/blood-2021-150175
Published: 2021
Journal Articles

R-CHOP Chemotherapy Including Biosimilar Rituximab (Redditux ®) for De-Novo Diffuse Large B-Cell Lymphoma Patients: Real-Life Single Center Experience

Murat Ozbalak, Metban Mastanzade, Ozden Ozluk, Tarik Onur Tiryaki, Simge Erdem, Ezgi Pınar Özbalak, Tuğrul Elverdi, Ipek Yonal Hindilerden, Mustafa Nuri Yenerel, Teoman Soysal, Meliha Nalcaci, Burhan Ferhanoglu, Sevgi Kalayoglu Besisik
Journal: Blood
Blood (2021) 138 (Supplement 1): 4585.
https://doi.org/10.1182/blood-2021-145810
Published: 2021
Journal Articles

Multicenter Early Access Program Results from Turkey: Efficacy and Safety of Daratumumab Among Heavily Pretreated Relapse/Refractory Multiple Myeloma Patients

Meral Beksac, MD, Yildiz Aydin, MD, Hakan Goker, MD, Mehmet Turgut, MD, Sevgi Kalayoglu Besisik, Seckin Cagirgan, Tulin F Tuglular, MD, Filiz Vural, MD, Munci Yagci, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 5442.
https://doi.org/10.1182/blood.V130.Suppl_1.5442.5442
Published: 2017
Journal Articles

Updated Efficacy and Safety, and Exploratory Ki-67 Results For The MCL-001 Study Of Lenalidomide In Mantle Cell Lymphoma Patients Who Relapsed Or Were Refractory To Bortezomib

Andre Goy, MD, Michael E. Williams, MD, ScM, Sevgi Kalayoglu Besisik, MD, Johannes Drach, Radhakrishnan Ramchandren, MD, Michael J. Robertson, MD, Irit Avivi, MD, Jacob M Rowe, MD, Raoul Herbrecht, MD, Achiel Van Hoof, Miklos Egyed, Lei Zhang, Sherri Cicero, Tommy Fu, Carla Heise, PhD, Thomas E Witzig, MD
Journal: Blood
Blood (2013) 122 (21): 3057.
https://doi.org/10.1182/blood.V122.21.3057.3057
Published: 2013
Journal Articles

Phase II Multicenter Study of Single-Agent Lenalidomide in Subjects with Mantle Cell Lymphoma Who Relapsed or Progressed After or Were Refractory to Bortezomib: The MCL-001 “EMERGE” Study

Andre Goy, MD, Rajni Sinha, MD, MRCP, Michael E. Williams, M.D., Sevgi Kalayoglu Besisik, Johannes Drach, Radhakrishnan Ramchandren, MD, Michael J. Robertson, MD, Irit Avivi, MD, Jacob M. Rowe, Raoul Herbrecht, MD, Achiel Van Hoof, Miklos Egyed, MD, PhD, Lei Zhang, MD, Sherri Cicero, Tommy Fu, Thomas E. Witzig, MD
Journal: Blood
Blood (2012) 120 (21): 905.
https://doi.org/10.1182/blood.V120.21.905.905
Published: 2012